vs
Side-by-side financial comparison of Neuphoria Therapeutics Inc. (NEUP) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
Americas Gold & Silver Corp is the larger business by last-quarter revenue ($19.1M vs $15.0M, roughly 1.3× Neuphoria Therapeutics Inc.). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs -82.3%, a 157.4% gap on every dollar of revenue.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
NEUP vs USAS — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $19.1M |
| Net Profit | $11.3M | $-15.7M |
| Gross Margin | — | 34.2% |
| Operating Margin | 79.8% | — |
| Net Margin | 75.1% | -82.3% |
| Revenue YoY | — | -28.0% |
| Net Profit YoY | — | 2.8% |
| EPS (diluted) | $6.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $19.1M | ||
| Q1 25 | $15.0M | — | ||
| Q3 24 | — | $26.5M |
| Q3 25 | — | $-15.7M | ||
| Q1 25 | $11.3M | — | ||
| Q3 24 | — | $-16.2M |
| Q3 25 | — | 34.2% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 23.6% |
| Q3 25 | — | — | ||
| Q1 25 | 79.8% | — | ||
| Q3 24 | — | — |
| Q3 25 | — | -82.3% | ||
| Q1 25 | 75.1% | — | ||
| Q3 24 | — | -60.9% |
| Q3 25 | — | — | ||
| Q1 25 | $6.55 | — | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | $39.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.0M | $50.2M |
| Total Assets | $30.7M | $234.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $39.1M | ||
| Q1 25 | $17.0M | — | ||
| Q3 24 | — | — |
| Q3 25 | — | $50.2M | ||
| Q1 25 | $26.0M | — | ||
| Q3 24 | — | $53.1M |
| Q3 25 | — | $234.7M | ||
| Q1 25 | $30.7M | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.5M | $-12.5M |
| Free Cash FlowOCF − Capex | — | $-41.3M |
| FCF MarginFCF / Revenue | — | -216.5% |
| Capex IntensityCapex / Revenue | — | 150.8% |
| Cash ConversionOCF / Net Profit | 1.02× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-12.5M | ||
| Q1 25 | $11.5M | — | ||
| Q3 24 | — | $2.4M |
| Q3 25 | — | $-41.3M | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-11.2M |
| Q3 25 | — | -216.5% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -42.2% |
| Q3 25 | — | 150.8% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 51.2% |
| Q3 25 | — | — | ||
| Q1 25 | 1.02× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
